Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes.
Leuk Res
; 37(3): 312-9, 2013 Mar.
Article
em En
| MEDLINE
| ID: mdl-23153525
ABSTRACT
We have previously demonstrated that two prognostic features of myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML), mutant NRAS and over-expressing BCL-2, cooperate physically and functionally in vivo. Screening of MDS patient bone marrow (BM) identified NRASBCL-2 co-localization in 64% cases, correlating with percentage BM blasts, apoptotic features and disease status (p<0.0001). Localization of the complex at the plasma membrane or the mitochondria correlated with disease and apoptosis features in MDS patients, whilst caspase-9 mediated mechanism was elucidated in vivo and in vitro. The intensity and localization of the RASBCL-2 complex merits further evaluation as a novel biomarker of MDS.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Síndromes Mielodisplásicas
/
Apoptose
/
Proteínas ras
/
Proteínas Proto-Oncogênicas c-bcl-2
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article